Drug Profile

LY 3076226

Alternative Names: anti-FGFR3 Ab IMC-D11; LY3076226

Latest Information Update: 27 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eli Lilly and Company
Class Antineoplastics; Bacterial toxins; Drug conjugates; Immunotoxins; Maytansinoids
Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Cancer

Most Recent Events

27 May 2024 LY 3076226 is still in phase I trial for Cancer (Late-stage disease, Metastatic disease) in USA (IV) (Eli Lilly and Company Pipleine, May 2024)
12 Feb 2024 ImmunoGen has been acquired by AbbVie
28 Apr 2019 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease) in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com